Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warfarin dosing test

This article was originally published in The Gray Sheet

Executive Summary

Kimball Genetics joins the small number of labs performing pharmacogenetic tests for warfarin therapy with the launch of its Warfarin DoseAdvise June 5. The test, performed at Kimball's CLIA-certified lab in Denver, analyzes genes in blood or cheek cell samples to inform dosing of the common blood thinner. According to Kimball CEO Annette Taylor, FDA plans to revise warfarin product labeling to advocate genetic testing. Other labs offering warfarin dosing tests include Clinical Data (PGxPredict). Third Wave, which sells reagents for warfarin tests, is developing the Invader warfarin in vitro diagnostic (1"The Gray Sheet" March 6, 2006, p. 12)...

You may also be interested in...



Third Wave, Now An IVD Company, Is Banking On Personalized Medicine

Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business

Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders

Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel